Overview

Effect of Pioglitazone on Oxidative Load, Inflammatory End-Points and Vascular Reactivity in Obese Non-Diabetic Patients: A Dose Ranging Study

Status:
Completed

Trial end date:
2003-10-01

Target enrollment:

Participant gender:

Summary

Pioglitazone decreases oxidative load, inflammatory end points and improves vascular reactivity in obese patients in a dose dependent manner and that this effect is independent of its glucose lowering effects.

Phase:

Phase 4

Details

Lead Sponsor:

University at Buffalo

Collaborator:

Takeda Pharmaceuticals North America, Inc.

Treatments:

Pioglitazone